In the latest twist in an ongoing patent case with far-reaching implications, the U.S. Supreme Court will consider Amgen’s petition seeking review of an appeals court decision that invalidated the company’s patent for its blockbuster cholesterol drug Repatha (evolocumab).
Source: Drug Industry Daily